直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Article

Introduction to Intellectual Property: A U.S. Perspective

March 27, 2015

Cold Spring Harbor Perspectives in Medicine

By Thomas Lee Irving; Amanda K. Murphy, Ph.D.; *Stacy D. Lewis

Many biotechnology innovators opt for patents, which grant legal, time-limited monopolies to eligible inventions. To obtain a patent in the United States, an invention must be useful to the public and made or altered by the hand of man. It must then clear the hurdles of novelty and nonobviousness. If an invention can do that, obtaining a patent becomes a matter of form: Who qualifies as an inventor? Does the application demonstrate possession, stake a clear claim to the protection sought, and enable “ordinary” colleagues to replicate it? Has the inventor purposely withheld anything? In this article, Finnegan attorneys Thomas L. Irving, Amanda K. Murphy, and Michael A. Stramiello address each of these hurdles as they apply to biotech inventions.

*Stacy Lewis is a law clerk at Finnegan.

Tags

patent-eligible, claim construction

Related Practices

Prosecution and Portfolio Management

Trade Secrets

Related Industries

Life Sciences

Biotechnology

Related Offices

Washington, DC

Related Professionals

Amanda K. Murphy, Ph.D.
Partner
London
+44 (0)20 7864 2814
Email

Originally printed in Cold Spring Harbor Perspectives in Medicine. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm's clients.

Related Insights

Lecture

IPIC/McGill Summer IP Course 2026: Understanding Trademarks

July 14, 2026

Montreal

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

2026 Copyright Society Annual Meeting

June 14-16, 2026

Louisville

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP